ライフサイエンスコーパス: IGFBP-4

1 horylation after the addition of recombinant IGFBP-4.

2 , indicating that the single 25-kDa IGFBP is IGFBP-4.

3 Using a series of IGFBP-4/5 chimeras and IGFBP-5 points mutants, we demons

4 lative to SMP8-BP4 mice, indicating that the IGFBP-4.7A protein was stabilized in vivo.

5 Thus, IGFBP-4.7A results in greater growth inhibition than equ

6 Myc-tagged native and IGFBP-4.7A retained equivalent IGF-I binding affinity.

7 FBP-4 was cleaved by SMC-conditioned medium, IGFBP-4.7A was completely resistant to proteolysis.

8 nsulin-like growth factor binding protein-4 (IGFBP-4), a well documented inhibitor of the IGF-1/IGF-1

9 studied in the presence of exogenously added IGFBP-4, a potent inhibitor of IGF-II actions in bone ce

10 e IGFBP-5 siRNA did not change the levels of IGFBP-4, a structurally related protein, or glyceraldehy

11 Therefore, IGFBP-4 and IGFBP-5 appear to be differentially regulate

12 reted IGF-I in controlling the expression of IGFBP-4 and IGFBP-5 as well as the effects of these IGFB

13 notoxic stressors may promote the release of IGFBP-4 and the molecular pathways associated with the i

14 Intact IGFBP-4 and the two IGFBP-4 fragments generated upon cle

15 Intact IGFBP-4 and two IGFBP-4 fragments were determined by a n

16 ortas had 8- to 20-fold increases in PAPP-A, IGFBP-4, and IGF-I mRNA levels compared with nonlesional

17 several forms of IGFBPs, including IGFBP-2, IGFBP-4, and IGFBP-5.

18 at the molecular identity of this protein is IGFBP-4, and that this binding protein may antagonize th

19 tly (Ki = 68 pm) inhibits PAPP-A cleavage of IGFBP-4, and we show in a cell-based assay that STC1 eff

20 hern blotting confirmed that transcripts for IGFBP-4 as well as IGF-I are expressed in thymic macroph

21 r to extend beyond the regulation of IGF and IGFBP-4, as neither PAPP-A nor STC2 were discernibly aff

22 The IGFBP-4 binding assay may be expanded to other IGFBP mem

23 Addition of IGFBP-4 blocked IGF-I- but not IGFBP-5-induced cell prol

24 A putative 278-bp IGFBP-4 cDNA fragment (residues 341-618) of rat) that co

25 Addition of protease-resistant IGFBP-4 completely abolished the PAPP-A-induced prolifer

26 IGF-I and IGFBP-4 concentrations were markedly altered in patients

27 ions at IGFBP-4 using a biotinylated form of IGFBP-4 coupled to streptavidin-coated polyvinyltoluene

28 Blocking the activity of IGFBP-4 did not significantly modulate the effect of IGF

29 We report for the first time that IGFBP-4 differentially inhibits angiogenesis induced by

30 transiently expressed IGFBP-5-EGFP, but not IGFBP-4-EGFP, is localized in the nuclei of VSMCs.

31 nsulin-like growth factor binding protein-4 (IGFBP-4) exerts its inhibitory effects on insulin-like g

32 Deletion analysis using IGFBP-4 expressed in bacteria revealed that the N-termin

33 Intact IGFBP-4 and the two IGFBP-4 fragments generated upon cleavage by PAPP-A were

34 Intact IGFBP-4 and two IGFBP-4 fragments were determined by a novel immunoassay

35 h is the major structural determinant of the IGFBP-4 function.

36 contrast to IGFBP-5, local administration of IGFBP-4 had no significant effect on bone formation in C

37 itor of IGF action in vitro, and cleavage of IGFBP-4 has been shown to abolish its ability to inhibit

38 IGFBP-2 was present in all samples, IGFBP-4 in sporadic samples, and BP-3 in group II-III sa

39 The concentrations of IGFBP-4 in the conditioned medium increased significantl

40 hibition of PAPP-A and increased cleavage of IGFBP-4 in vitro, resulting in higher bioavailability of

41 inhibition than equivalent levels of native IGFBP-4 in vivo, demonstrating a role for IGFBP-4 proteo

42 plore the function of the protease-resistant IGFBP-4 in vivo, expression of the mutant and native pro

43 distinct growth factor signaling pathways as IGFBP-4 inhibited FGF-2- and IGF-1-stimulated angiogenes

44 When added together with IGF-I, exogenous IGFBP-4 inhibited IGF-I-induced DNA synthesis in a conce

45 esistance of VEGF-stimulated angiogenesis to IGFBP-4 inhibition appears to depend on sustained activa

46 creening platforms for the identification of IGFBP-4 inhibitors.

47 Intact IGFBP-4 is a potent inhibitor of IGF action in vitro, an

48 ased precipitation of [(125)I]IGF-1 bound to IGFBP-4 is used to quantify selective IGFBP-4 ligand int

49 3 (2-3-fold) and mRNA (1.5-2-fold), whereas IGFBP-4 levels remained essentially unchanged.

50 und to IGFBP-4 is used to quantify selective IGFBP-4 ligand interactions.

51 Increased level of circulating IGFBP-4 may be responsible of pro-aging effect.

52 hibit the ability of IGF-1 to associate with IGFBP-4 may have clinical utility as regulators of cellu

53 Thus, IGFBP-4 may modulate IGF bioavailability in IBD.

54 vasculature at Day (d) 8.0, both IGFBP-3 and IGFBP-4 mRNAs are detected in dilating blood vessels, wi

55 s high levels of IGFBP-3 and lower levels of IGFBP-4 mRNAs.

56 Mitogenic studies revealed that an IGFBP-4 mutant (His74 replaced by Pro74) and an N-termin

57 In contrast, an IGFBP-4 mutant (His74 replaced with Ala74) exhibited sim

58 The IGFBP-4 N-domain had modest activity.

59 vity restored the anti-angiogenic effects of IGFBP-4 on VEGF-induced blood vessel growth in vivo.

60 3 was a more potent ligand for TbetaR-V than IGFBP-4 or -5.

61 ival to the control level; overexpression of IGFBP-4 or wild type IGFBP-5 had no such effect.

62 Concentrations of IGFBP-4, PAPP-A, and STC2 on day 0 and 7 were compared t

63 nst PAPP-A both inhibited and immunodepleted IGFBP-4 protease activity in human fibroblast-conditione

64 rified from pregnancy sera had IGF-dependent IGFBP-4 protease activity.

65 IGFBP-4 protease(s) recognizes basic residues within the

66 crease in the activity of an IGF-I-regulated IGFBP-4 protease.

67 , antisense ODN did not significantly affect IGFBP-4 protein or mRNA levels, strongly supporting the

68 mical and physical stress, we identified the IGFBP-4 protein that can be considered a general stress

69 cts in a variety of systems, suggesting that IGFBP-4 proteolysis acts as a positive regulator of IGF

70 ve IGFBP-4 in vivo, demonstrating a role for IGFBP-4 proteolysis in the regulation of IGF-I action.

71 such as low dose irradiation, may promote an IGFBP-4 release in bloodstream both in mice irradiated w

72 reduced IGF-binding protein 3 (IGFBP-3) and IGFBP-4 RNA.

73 Cs and that endoglin-dependent regulation of IGFBP-4 secretion was crucial for stromal cell-condition

74 Under optimized conditions, the IGFBP-4 SPA was stable for up to 24h at room temperature

75 we report the isolation of an IGF-dependent IGFBP-4-specific protease from human fibroblast-conditio

76 nsulin-like growth factor-binding protein 4 (IGFBP-4), the most abundant IGF-binding protein produced

77 erent effects on levels of STC2, PAPP-A, and IGFBP-4, thereby explaining the distinct metabolic effec

78 Bladder and aortic immunoreactive IGFBP-4/transgene mRNA ratios in SMP8-BP4.7A mice were i

79 ce that were intraperitoneally injected with IGFBP-4 twice a week for two months.

80 PAPP-A can cleave IGF binding protein-4 (IGFBP-4), upon which IGF-I is liberated.

81 for measuring small molecule interactions at IGFBP-4 using a biotinylated form of IGFBP-4 coupled to

82 Whereas native IGFBP-4 was cleaved by SMC-conditioned medium, IGFBP-4.7

83 s two unique cysteine residues found only in IGFBP-4 was cloned and sequenced from thymic macrophages

84 f individual IGFBPs were tested, IGFBP-2 and IGFBP-4 were found to inhibit IGF-I-stimulated DNA synth

85 nsulin-like growth factor-binding protein 4 (IGFBP-4), which exists in many different tissues and bio

86 We constructed a mutant IGFBP-4 with the cleavage domain substitution 119-KHMAKV